Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Customer Focus - Physician/Prescribing

Sponsored by

Finalist

Psoriatic Arthritis (PsA) Assessment Academy

Abbott in association DNA Medical Communications


Summary of work

A new modular approach for rheumatologists and dermatologists to assess and diagnose psoriatic arthritis (PsA), has transformed psoriatic arthritis (PsA) management. 

Developed by six leading KOLs, this is the first clear guidance on the assessment process for PsA. The credibility and quality is demonstrated through endorsement by two UK professional bodies. It was also used as the standard assessment approach in an independent UK‐wide clinical trial (18 centres) on long‐term outcomes in PsA. 

In addition, 34 clinics are implementing the modular approach (double the target) and 250 toolkits have been disseminated (20 per cent above target). Guy’s Hospital, London, readily adopted this new approach – routine use of the new screening guidance/note pads (which were developed to support the modular approach) in over 100 people highlighted previously undiagnosed spondylitis that otherwise would have been missed, clearly demonstrating the impact of this programme on earlier diagnosis and treatment of patients with PsA.

 

 

Executive summary as submitted


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics